jobs

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ayala Pharmaceuticals Inc (OP: ADXS )

0.1051 +0.0780 (+287.82%)
Streaming Delayed Price Updated: 9:30 AM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ayala Pharmaceuticals Inc

Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
From Ayala Pharmaceuticals
Via GlobeNewswire
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
From Ayala Pharmaceuticals
Via GlobeNewswire
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
From Ayala Pharmaceuticals
Via GlobeNewswire
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
From Immunome, Inc.
Via Business Wire
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile 
From Ayala Pharmaceuticals
Via GlobeNewswire
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
From Ayala Pharmaceuticals
Via GlobeNewswire
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
From Ayala Pharmaceuticals
Via GlobeNewswire
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
From Ayala Pharmaceuticals
Via GlobeNewswire
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
From Ayala Pharmaceuticals
Via GlobeNewswire
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
From Ayala Pharmaceuticals
Via GlobeNewswire
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
From Ayala Pharmaceuticals
Via GlobeNewswire
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
From Ayala Pharmaceuticals
Via GlobeNewswire
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Ayala Pharmaceuticals
Via GlobeNewswire
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Ayala Pharmaceuticals
Via GlobeNewswire
Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update
From Ayala Pharmaceuticals
Via GlobeNewswire
Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Poster will feature updated results from Phase 2 portion of RINGSIDE, evaluating AL102 in desmoid tumors 
From Ayala Pharmaceuticals
Via GlobeNewswire
Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee
From Ayala Pharmaceuticals
Via GlobeNewswire
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022
From Ayala Pharmaceuticals
Via GlobeNewswire
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
From Ayala Pharmaceuticals
Via GlobeNewswire
ADXS Investor Alert – Monteverde & Associates PC and Kahn Swick & Foti, LLC Obtain Material Disclosures Regarding the Upcoming Shareholder Vote for Advaxis, Inc. - ADXS
From Kahn Swick & Foti, LLC
Via Business Wire
INVESTIGATION: Halper Sadeh LLP Investigates LONE, KIN, GRA, ADXS; Shareholders are Encouraged to Contact the Firm
NEW YORK, NY / ACCESSWIRE / July 22, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Lonestar Resources US Inc. (OTCQX:LONE)... 
From Halper Sadeh LLP
Via AccessWire
Topics Fraud
Exposures Legal
INVESTIGATION ALERT: Halper Sadeh LLP Investigates JAX, STMP, IKNX, ADXS; Shareholders are Encouraged to Contact the Firm
NEW YORK, NY / ACCESSWIRE / July 11, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: J. Alexander's Holdings, Inc. (NYSE:JAX)... 
From Halper Sadeh LLP
Via AccessWire
Topics Fraud
Exposures Legal
INVESTIGATION ALERT: Halper Sadeh LLP Investigates CORE, CAI, BOCH, ADXS; Shareholders are Encouraged to Contact the Firm
NEW YORK, NY / ACCESSWIRE / July 10, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Core-Mark Holding Company, Inc.... 
From Halper Sadeh LLP
Via AccessWire
Topics Fraud
Exposures Legal
ADVAXIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Advaxis, Inc. - ADXS
From Kahn Swick & Foti, LLC
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News Instagram Instagram
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

922 Allowance Ave SE
Medicine Hat, AB T1A 3G7

Office hours: 8:30 a.m.-4:30 p.m. Monday to Friday, closed Saturday Sunday and statutory holidays.

[P] 403.527.1101
[F] 403-527-0737

Print Advertising: 403.528.5659
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2024 The Medicine Hat News